The 2021 ASPC Preventive Cardiology Experts Course (PCEC) was live in Las Vegas October 1-2, 2021 and was led by key experts and leaders in the field. This program will be available OnDemand from November 1, 2021 - February 1, 2022. The course provides an in-depth review of the knowledge and skills necessary to successfully implement preventive therapies in cardiology. Primary and secondary prevention strategies including management of cardiovascular risk factors, therapeutic management, and lifestyle changes will be addressed. This series of lectures, provides an excellent update on core concepts in preventive cardiology.
The target audience for this course is the healthcare professional interested in intensive and in-depth preventive cardiology education including, but not limited to: cardiologists, lipidologists, endocrinologists, internists, family practitioners, osteopaths, and allied health care professionals.
The ASPC Preventive Cardiology Experts Course is $695 (ASPC member discounted fee is $595 and ASPC member's that are fellows in training are discounted to $295) and includes the Preventive Cardiology Manual 2nd Edition.
Activity Overview
The Enduring Experts Course is for health care professionals interested in intensive and in-depth preventive cardiology education. The Experts Course is led by key experts and leaders in the field and covers topics such as heart failure, atrial fibrillation, diabetes, Familial Hypercholesterolemia, anticoagulants and more. The course will be accredited for approximately (TBD) AMA PRA Category 1 Credit(s)™.
Target Audience
This activity is designed for an audience of physicians, physician assistants, nurses, pharmacists, dieticians, research scientists and other healthcare professionals.
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Critically Evaluate the benefit of physical activity has on CVD risk reduction and define strategies to incorporate behavior into daily clinical practice.
- Assess the clinical benefits, mechanisms, and safety profiles of new and emerging anti-obesity medications.
- Describe the link between cardiovascular and metabolic disease and discuss potential pharmacological strategies.
- Summarize the evidence-based recommendations for therapeutic interventions to reduce the risk for cardiovascular complications among patients with type 2 diabetes.
- Recognize the gender differences in treatment and outcomes in CVD Prevention.
- Assess the cardiovascular risks of testosterone replacement therapy.
- Evaluate the application and limitations of lipid and non-lipid biomarkers and risk assessment tools for cardiovascular risk detection.
- Understand how to properly manage stroke patients with aggressive lipid lowering therapy to reduce their likelihood of a second stroke.
- Recognize and understand the pathophysiological role of inflammation in cardiovascular disease.
- Identify the causes and classification of elevated triglycerides, the clinical manifestations of primary hypertriglyceridemia and the management of patients with elevated triglyceride levels.
- Summarize the role of therapeutic agents for stroke prevention in patients with atrial fibrillation.
- Analyze and discuss new treatments for heart failure so clinicians can utilize effective treatments in practice.
- Outline current patient guidelines on the diagnosis, management, and treatment of hypertension.
- Translate clinical trial data of PCSK9 inhibitors to the individualized and targeted management approach of high-risk hypercholesterolemia patients.
- Educate clinicians on the issues associated with CVD in minorities and discuss effective strategies for prevention.
- Describe evidence-based clinical strategies to reduce cardiovascular risk in patients with chronic kidney disease.
- Educate clinicians on the relationship of sleep apnea and the risks of cardiovascular consequences.
- Evaluate the use of imaging and stress testing in the treatment of cardiovascular disease prevention.
- Understand ASCVD and the risk assessment tools that are available for clinicians to use to estimate their patient’s risk.
- Educate clinicians on the importance of polygenic Scoring and its relation to Predication and prevention of ASCVD.
- Review the evidence for dual antiplatelet versus monotherapy strategies for patients with CAD.
- Understand the clinical data with stents and prevention of coronary artery disease.
- Critically evaluate the literature involving diets to reduce cardiovascular risk and implement this knowledge into clinical practice.
- Critically evaluate coronary CT angiography and discuss best practices to implement into clinical practice.
- Evaluate the medical and lifestyle management of PAD that incorporate therapies to improve functional outcomes, reduce adverse cardiovascular, and limb events.
- Explain new management strategies associated with peripheral venous disease.
- Educate clinicians on coronary calcium scoring and discuss best practices to implement into clinical practice.
Criteria for Success
Certificates of completion will be awarded based on the participant’s attendance, completion of pre-test and submission of the activity evaluation/claim credit and post-test form at http://akhinc.formstack.com/forms/20281 after October 2, 2021. If you have questions about this activity, please contact AKH Inc. at lritley@akhcme.com.
Credit provided by AKH Inc., Advancing Knowledge in Healthcare and The American Society for Preventive Cardiology.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and The American Society for Preventive Cardiology. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of (TBD) AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of the CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.75 medical knowledge MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
AAPA Credit Designation Statement
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 16.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Commercial Support
Full notification of commercial support will be provided in the final course syllabus.
ASPC’s 2021 Preventive Cardiology Experts Course
Chair: Peter P. Toth, MD, PhD, FASPC
AGENDA
|
Session 1
|
Moving your Way to a Healthier Heart: Physical Activity, Fitness and Reduction of Sitting Time on CVD risk Erin Michos, MD, MHS, FASPC |
|
Session 2
|
Obesity and the Facilitation of Weight Loss Jaime Almandoz, MD |
|
Session 3
|
Novel Cardiovascular Concepts of Humor and Standup Comedy Harold Bays, MD, FASPC |
|
Session 4
|
Intelligent Drug Choices in the Management of non-insulin-dependent Diabetes Mellitus Peter Wilson, MD |
|
Session 5
|
Evaluating Chest Pain and Myocardial Ischemia in Women Martha Gulati, MD, MS, FASPC |
|
Session 6
|
Testosterone Supplementation and Risk of Cardiovascular Events-What do you tell a Man? Stephen Kopecky, MD, FASPC |
|
Session 7
|
Integrating Advanced Lipid Testing and CV Biomarkers in Assessment and Treatment Pam Taub, MD, FASPC |
|
Session 8
|
LDL-C and the Brain: Differentiating Fact From Fiction Peter Toth, MD, PhD, FASPC |
|
Session 9
|
Role of Inflammation in Atherogenesis: Current Understanding and Future Perspectives Salim Virani, MD, PhD, FASPC |
|
Session 10
|
Hypertriglyceridemia: Sheep or Shepard? Seth Baum, MD, FASPC |
|
Session 11
|
Atrial Fibrillation: Management and Anticoagulation Howard Weintraub, MD, FASPC |
|
Session 12
|
State of the Art Management of Heart Failure Javed Butler, MD, PhD, MBA |
|
Session 13 |
State of the Art Management of Hypertension Daniel Duprez, MD, PhD, FASPC |
|
Session 14
|
PCSK9 Therapy for Patients with Familial Hypercholesterolemia Peter Toth, MD, PhD, FASPC |
|
Session 15
|
Issues in CVD Prevention in Minority Populations Keith Ferdinand, MD, FASPC |
|
Session 16
|
Diagnosis and Management of Chronic Kidney Disease Daniel Duprez, MD, PhD |
|
Session 17
|
Obstructive sleep Apnea: It is Time for Us to Wake Up and Make the Diagnosis Virend Somers, MD |
|
Session 18
|
Integrating Imaging and Stress Testing in Assessment and Treatment (A Preventive Cardiologist’s View) Amit Khera, MD, MSc, FASPC |
|
Session 19
|
ASCVD Risk Assessment: Global Risk Scoring and Beyond Nathan Wong, PhD, MPH, FASPC |
|
Session 20
|
Polygenic Scoring for ASCVD Prediction and Prevention; Is it ready for Prime Time? Amit V. Khera, MD, MSc |
|
Session 21
|
Antiplatelet Agents in Primary and Secondary Prevention: When Are They Indicated? Ann Marie Navar, MD, PhD, FASPC |
|
Session 22
|
Coronary Stenting: Is it Really Preventive? Tracing The Evolution of PCI and Optimal Medical Therapy over the Past 40+ Years William Boden, MD |
|
Session 23
|
Peripheral Arterial Disease: Diagnosis and Treatment Marc Bonaca, MD, MPH |
|
Session 24
|
What Exactly is a cardiac Diet and how should it be structured? Stephen Kopecky, MD, FASPC |
|
Session 25
|
Coronary CT Angiography Ron Blankstein, MD, FASPC |
|
Session 26
|
Management Issues in Peripheral Venous Disease Alison Bailey, MD, FASPC |
|
Session 27
|
Coronary Artery Calcium CT Scan: Who, What, When? Heather Johnson, MD, FASPC |